Cargando…

Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report

BACKGROUND: We present this case to draw attention to the importance of early diagnosis in terms of life-saving, noting that greater awareness is important among healthcare professionals. Our patient developed neuroleptic malignant syndrome (NMS) after his neuroleptic drug dosage was increased. His...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chee Keong, Payus, Alvin Oliver, Noh, Malehah Mohd, Lansing, Meryl Grace, Sumpat, Doreen, Lu, Sooth Jiun Andrea, Yew, Boon Teong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535839/
https://www.ncbi.nlm.nih.gov/pubmed/36203196
http://dx.doi.org/10.1186/s13256-022-03591-5
_version_ 1784802859492048896
author Chang, Chee Keong
Payus, Alvin Oliver
Noh, Malehah Mohd
Lansing, Meryl Grace
Sumpat, Doreen
Lu, Sooth Jiun Andrea
Yew, Boon Teong
author_facet Chang, Chee Keong
Payus, Alvin Oliver
Noh, Malehah Mohd
Lansing, Meryl Grace
Sumpat, Doreen
Lu, Sooth Jiun Andrea
Yew, Boon Teong
author_sort Chang, Chee Keong
collection PubMed
description BACKGROUND: We present this case to draw attention to the importance of early diagnosis in terms of life-saving, noting that greater awareness is important among healthcare professionals. Our patient developed neuroleptic malignant syndrome (NMS) after his neuroleptic drug dosage was increased. His condition was complicated by acute kidney injury (AKI) which required hemodialysis. The uniqueness of this case is that the causative agent of NMS is an atypical antipsychotic, and atypical antipsychotics are generally considered to be safer than typical antipsychotics. CASE PRESENTATION: A 31-year-old Chinese man with underlying schizophrenia presented to our hospital with aggressive behavior. He was admitted to the psychiatric hospital and started on his regular medications, with an increase in the dose of olanzapine tablet from 5 to 10 mg daily. After 5 days in the ward, the patient was noted to have high fever, restlessness, confusion, increased muscle rigidity, tachycardia and tachypnoea. Antipsychotic therapy was stopped in view of suspected NMS. The first laboratory test for serum creatine kinase (CK) showed a markedly high level of this molecule. His renal profile showed raised serum creatinine in comparison to 2 months prior when the baseline serum creatinine was within the normal range. A diagnosis of NMS with AKI was made. Although the patient was given adequate intravenous fluid hydration with close monitoring of urine output, his renal function did not show improvement but continued to show a worsening trend. In view of this, he was started on urgent hemodialysis. The patient was dependent on intermittent hemodialysis before his AKI showed complete recovery. After 2 weeks, his blood test results returned to normal. He was discharged well. CONCLUSION: Neuroleptic malignant syndrome is a life-threatening iatrogenic medical emergency in which high index of clinical suspicion is required for diagnosis and prompt treatment.
format Online
Article
Text
id pubmed-9535839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95358392022-10-07 Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report Chang, Chee Keong Payus, Alvin Oliver Noh, Malehah Mohd Lansing, Meryl Grace Sumpat, Doreen Lu, Sooth Jiun Andrea Yew, Boon Teong J Med Case Rep Case Report BACKGROUND: We present this case to draw attention to the importance of early diagnosis in terms of life-saving, noting that greater awareness is important among healthcare professionals. Our patient developed neuroleptic malignant syndrome (NMS) after his neuroleptic drug dosage was increased. His condition was complicated by acute kidney injury (AKI) which required hemodialysis. The uniqueness of this case is that the causative agent of NMS is an atypical antipsychotic, and atypical antipsychotics are generally considered to be safer than typical antipsychotics. CASE PRESENTATION: A 31-year-old Chinese man with underlying schizophrenia presented to our hospital with aggressive behavior. He was admitted to the psychiatric hospital and started on his regular medications, with an increase in the dose of olanzapine tablet from 5 to 10 mg daily. After 5 days in the ward, the patient was noted to have high fever, restlessness, confusion, increased muscle rigidity, tachycardia and tachypnoea. Antipsychotic therapy was stopped in view of suspected NMS. The first laboratory test for serum creatine kinase (CK) showed a markedly high level of this molecule. His renal profile showed raised serum creatinine in comparison to 2 months prior when the baseline serum creatinine was within the normal range. A diagnosis of NMS with AKI was made. Although the patient was given adequate intravenous fluid hydration with close monitoring of urine output, his renal function did not show improvement but continued to show a worsening trend. In view of this, he was started on urgent hemodialysis. The patient was dependent on intermittent hemodialysis before his AKI showed complete recovery. After 2 weeks, his blood test results returned to normal. He was discharged well. CONCLUSION: Neuroleptic malignant syndrome is a life-threatening iatrogenic medical emergency in which high index of clinical suspicion is required for diagnosis and prompt treatment. BioMed Central 2022-10-06 /pmc/articles/PMC9535839/ /pubmed/36203196 http://dx.doi.org/10.1186/s13256-022-03591-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Chang, Chee Keong
Payus, Alvin Oliver
Noh, Malehah Mohd
Lansing, Meryl Grace
Sumpat, Doreen
Lu, Sooth Jiun Andrea
Yew, Boon Teong
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title_full Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title_fullStr Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title_full_unstemmed Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title_short Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
title_sort neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535839/
https://www.ncbi.nlm.nih.gov/pubmed/36203196
http://dx.doi.org/10.1186/s13256-022-03591-5
work_keys_str_mv AT changcheekeong neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT payusalvinoliver neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT nohmalehahmohd neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT lansingmerylgrace neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT sumpatdoreen neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT lusoothjiunandrea neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport
AT yewboonteong neurolepticmalignantsyndromesecondarytoolanzapineapresentationwithsevereacutekidneyinjuryrequiringhemodialysisacasereport